Ospedale di Livorno
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 · Benjamin Solomon, Tony Mok, et al. · New England Journal of Medicine
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
2010 · Wendy De Roock, Bart Claes, et al. · The Lancet Oncology
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
2015 · Naiyer A. Rizvi, Julien Mazières, et al. · The Lancet Oncology